Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from Lyra Therapeutics ( (LYRA) ) is now available.
On June 13, 2025, Lyra Therapeutics, Inc. received a notification from Nasdaq confirming that its common stock maintained a minimum bid price of $1.00 or more for 12 consecutive business days, from May 28, 2025, to June 12, 2025. This achievement means the company has regained compliance with Nasdaq’s Listing Rule 5550(a)(2), closing the matter.
The most recent analyst rating on (LYRA) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Neutral.
Lyra Therapeutics’ overall stock score is primarily impacted by its financial challenges, with consistent losses and reliance on external funding. Positive corporate events, including successful trial results and strategic advancements, provide some optimism. Technical analysis is mixed, suggesting cautious optimism, while valuation remains a concern due to ongoing losses.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Average Trading Volume: 675,304
Technical Sentiment Signal: Sell
Current Market Cap: $13.85M
See more insights into LYRA stock on TipRanks’ Stock Analysis page.